Bita Fakhri, Bita Fakhri, MD, MPH

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Abbvie
    Topic: 
    CLL
    Date added: 
    03/29/2024
    Relationship end date: 
    03/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    AstraZeneca
    Topic: 
    CLL
    Date added: 
    03/29/2024
    Relationship end date: 
    03/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Beigene
    Topic: 
    CLL
    Date added: 
    03/29/2024
    Relationship end date: 
    03/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    TG Therapeutics
    Topic: 
    CLL
    Date added: 
    03/29/2024
    Relationship end date: 
    03/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Adaptive
    Topic: 
    CLL
    Date added: 
    03/29/2024
    Relationship end date: 
    03/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Loxo/Lilly
    Topic: 
    CLL
    Date added: 
    03/29/2024
    Relationship end date: 
    03/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Pharmacyclics
    Topic: 
    CLL
    Date added: 
    03/29/2024
    Relationship end date: 
    03/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    BMS/Juno
    Topic: 
    CLL
    Date added: 
    03/29/2024
    Relationship end date: 
    03/31/2024
Return to Dogmas and Controversies in Hematologic Malignancies: West Coast Symposium